Fate Therapeutics, Inc.
FATE
$1.08
$0.087.46%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 5.34% | 9.44% | 27.86% | -9.39% | -24.07% |
| Total Depreciation and Amortization | -1.56% | -1.65% | -30.75% | 4.47% | -2.41% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -32.40% | 4.78% | -72.72% | 103.82% | 102.74% |
| Change in Net Operating Assets | 590.41% | 101.36% | -181.46% | -161.03% | 182.51% |
| Cash from Operations | 0.87% | 27.28% | -21.62% | 5.51% | 8.94% |
| Capital Expenditure | -61.75% | -13.88% | -1,120.41% | 80.20% | -870.59% |
| Sale of Property, Plant, and Equipment | -97.54% | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 12.68% | -52.52% | 91.45% | -11.72% | 148.68% |
| Cash from Investing | 8.58% | -54.09% | 87.03% | -10.39% | 147.70% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 86.79% | -- | -- | -- | -100.00% |
| Cash from Financing | 86.79% | -- | -- | -- | -100.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 82.92% | -141.41% | 578.36% | 53.18% | 95.31% |